AT336583T - Receptor based antagonists and method for the production and use thereof - Google Patents

Receptor based antagonists and method for the production and use thereof

Info

Publication number
AT336583T
AT336583T AT99952942T AT99952942T AT336583T AT 336583 T AT336583 T AT 336583T AT 99952942 T AT99952942 T AT 99952942T AT 99952942 T AT99952942 T AT 99952942T AT 336583 T AT336583 T AT 336583T
Authority
AT
Austria
Prior art keywords
production
use
method
receptor based
based antagonists
Prior art date
Application number
AT99952942T
Other languages
German (de)
Inventor
Neil Stahl
George D Yancopoulos
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US10185898P priority Critical
Priority to US09/313,942 priority patent/US6472179B2/en
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of AT336583T publication Critical patent/AT336583T/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
AT99952942T 1998-09-25 1999-09-22 Receptor based antagonists and method for the production and use thereof AT336583T (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10185898P true 1998-09-25 1998-09-25
US09/313,942 US6472179B2 (en) 1998-09-25 1999-05-19 Receptor based antagonists and methods of making and using

Publications (1)

Publication Number Publication Date
AT336583T true AT336583T (en) 2006-09-15

Family

ID=26798712

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99952942T AT336583T (en) 1998-09-25 1999-09-22 Receptor based antagonists and method for the production and use thereof
AT02007831T AT283365T (en) 1998-09-25 1999-09-22 Il-1 receptor fusion proteins used as an antagoniste and method for use and production thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02007831T AT283365T (en) 1998-09-25 1999-09-22 Il-1 receptor fusion proteins used as an antagoniste and method for use and production thereof

Country Status (18)

Country Link
US (2) US6472179B2 (en)
EP (3) EP1229047B1 (en)
JP (1) JP3902728B2 (en)
CN (1) CN100345970C (en)
AT (2) AT336583T (en)
AU (1) AU758970C (en)
BE (1) BE2010C021I2 (en)
CA (1) CA2345109C (en)
DE (3) DE69922269T2 (en)
DK (1) DK1229047T3 (en)
ES (2) ES2267300T3 (en)
HK (1) HK1035377A1 (en)
IL (2) IL142103D0 (en)
NO (2) NO329976B1 (en)
NZ (1) NZ510720A (en)
PL (1) PL201246B1 (en)
PT (1) PT1229047E (en)
WO (1) WO2000018932A2 (en)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
AT272114T (en) * 1998-01-23 2004-08-15 Immunex Corp Receptors for il-18
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US7083949B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US7083950B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
US20040120891A1 (en) * 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
WO2001092340A2 (en) 2000-05-26 2001-12-06 Immunex Corporation Use of interleukin-4 antagonists and compositions thereof
JP4660062B2 (en) * 2000-06-16 2011-03-30 アステリオン・リミテッド Binder
ES2381650T3 (en) 2000-08-08 2012-05-30 Zymogenetics, Inc. Soluble Zcytor11 cytokine receptors
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20050112616A1 (en) * 2001-12-10 2005-05-26 William Lee Functionalized materials and libraries thereof
US7795213B2 (en) * 2001-12-13 2010-09-14 Posco Methods of contacting β amyloid protein with VEGF
US6846520B2 (en) * 2002-01-17 2005-01-25 Canon Kabushiki Kaisha Epoxy resin composition, surface treatment method, liquid-jet recording head and liquid-jet recording apparatus
CA2480777A1 (en) * 2002-05-01 2003-11-13 Regeneron Pharmaceuticals, Inc. Methods of using cytokine antagonists to treat hiv infection and aids
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
AU2003295471B2 (en) * 2002-11-15 2011-08-25 Genmab A/S Human monoclonal antibodies against CD25
US6919012B1 (en) 2003-03-25 2005-07-19 Olimex Group, Inc. Method of making a composite article comprising a ceramic coating
JP2007533595A (en) 2003-03-26 2007-11-22 アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツングApogenix GmbH Treatment of viral infection
US20040224893A1 (en) * 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
WO2004098596A1 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising roflumilast and il-1 trap
WO2005014646A1 (en) * 2003-06-11 2005-02-17 Wyeth Method for producing a polypeptide
WO2005016968A2 (en) * 2003-07-28 2005-02-24 Genentech, Inc. Reducing protein a leaching during protein a affinity chromatography
CA2536936A1 (en) * 2003-09-05 2005-03-17 National Research Council Of Canada E- and k-coiled-coil fusion proteins comprising tgf-b cell receptor domains
US7786261B2 (en) * 2004-09-02 2010-08-31 National Research Council Of Canada Coiled-coil fusion proteins comprising cell receptor domains
ES2383809T3 (en) 2003-11-07 2012-06-26 Immunex Corporation Antibodies that bind to the interleukin 4 receptor
AT395358T (en) * 2004-02-27 2008-05-15 Regeneron Pharma IL-4 / IL-13-specific polypeptides and their therapeutic use
CN1964737B (en) 2004-06-04 2011-04-20 瑞泽恩制药公司 Methods of using IL-1 antagonists to treat autoinflammatory disease
CA2891010A1 (en) 2004-07-23 2006-02-02 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
EP2311871A3 (en) * 2004-08-17 2012-08-08 Regeneron Pharmaceuticals, Inc. IL-1 antagonist stable liquid formulation
ES2309427T3 (en) * 2004-08-27 2008-12-16 Conaris Research Institute Ag Sequences of optimized nucleotids coding for sgp130.
DE602005021811D1 (en) * 2004-09-13 2010-07-22 Genzyme Corp Multi-more constructs
MX2007004374A (en) * 2004-10-12 2008-01-29 Amprotein Corp Chimeric protein.
KR101238684B1 (en) 2004-10-22 2013-03-04 지모제넥틱스, 인코포레이티드 Anti-il-22ra antibodies and binding partners and methods of using in inflammation
WO2006079169A1 (en) * 2005-01-25 2006-08-03 Apollo Life Sciences Limited Parameter selected gm-csf, il-3, il-4, il-5 and chimeras thereof for therapeutic and diagnostic purposes
EP3195874A1 (en) * 2005-03-25 2017-07-26 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations
US7732167B2 (en) * 2005-06-17 2010-06-08 Regeneron Pharmaceuticals, Inc. Interferon-α/β binding fusion proteins and therapeutic uses thereof
US7608430B2 (en) * 2005-07-08 2009-10-27 Regeneron Pharmaceuticals, Inc. Interferon-γ antagonists and therapeutic uses thereof
EP2295080A3 (en) 2005-07-25 2011-06-22 Emergent Product Development Seattle, LLC B-cell reduction using CD37-specific and CD20-specific binding molecules
US7666622B2 (en) * 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
WO2007061981A2 (en) 2005-11-21 2007-05-31 Lumera Corporation Surface plasmon resonance spectrometer with an actuator-driven angle scanning mechanism
EP2781222B1 (en) * 2005-11-23 2017-08-02 Acceleron Pharma, Inc. Activin-actriia antagonists in use for promoting bone growth
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US7463358B2 (en) 2005-12-06 2008-12-09 Lumera Corporation Highly stable surface plasmon resonance plates, microarrays, and methods
DK1999154T3 (en) 2006-03-24 2012-12-03 Merck Patent Gmbh Manufactured heterodimered protein domains
NZ612319A (en) 2006-06-12 2015-04-24 Emergent Product Dev Seattle Single-chain multivalent binding proteins with effector function
DE602006016765D1 (en) 2006-06-30 2010-10-21 Conaris Res Inst Ag Improved sgp 130Fc dimer
US8106004B2 (en) * 2006-07-28 2012-01-31 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
AU2007279205B2 (en) * 2006-07-28 2013-09-26 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
US20080300185A1 (en) * 2006-10-20 2008-12-04 Catherine Vicary Use of IL-1 antagonists to treat gout and pseudogout
US7632490B2 (en) * 2006-10-20 2009-12-15 Regeneron Pharmaceuticals, Inc. Use of IL-1 antagonists to treat gout
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
JP5272735B2 (en) * 2007-01-30 2013-08-28 国立大学法人 新潟大学 Biologics
TWI480048B (en) 2007-02-01 2015-04-11 Acceleron Pharma Inc Activin-actriia antagonists and uses for treating or preventing breast cancer
TW201803890A (en) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 Variants derived from ActRIIB and uses therefor
DK2120999T3 (en) 2007-02-09 2012-12-03 Acceleron Pharma Inc Pharmaceutical compositions comprising Activin-ActRIIA antagonists and their use in the prevention or treatment of multiple myeloma
US7947646B2 (en) 2007-03-06 2011-05-24 Amgen Inc. Variant activin receptor polypeptides
SG10201605027XA (en) 2011-12-19 2016-08-30 Amgen Inc Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
WO2008113185A1 (en) 2007-03-19 2008-09-25 National Research Counsil Of Canada Antagonists of ligands and uses thereof
WO2009010539A2 (en) * 2007-07-19 2009-01-22 Ablynx. N.V. Receptor for interleukin-6 (il-6) from macaca fascicularis
JP2010539236A (en) 2007-09-18 2010-12-16 アクセルロン ファーマ, インコーポレイテッド Activin-ActRIIa Antagonist and Use for Reducing or Inhibiting FSH Secretion
WO2009058888A1 (en) * 2007-10-31 2009-05-07 The Scripps Research Institute Combination therapy to treat persistent viral infections
US8004669B1 (en) 2007-12-18 2011-08-23 Plexera Llc SPR apparatus with a high performance fluid delivery system
NZ621443A (en) 2008-04-11 2015-09-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
DK2340031T3 (en) 2008-08-14 2019-07-15 Acceleron Pharma Inc Gdf customer for use of analysis treatment
CA2737271A1 (en) * 2008-09-17 2010-03-25 National Research Council Of Canada Hetero-multivalent binding agents for members of the tgf.beta. superfamily
CR20160443A (en) 2008-11-26 2016-11-08 Amgen Inc Variants activin receptor polypeptides and applications thereof iib (divisional)
CA2764890A1 (en) 2009-06-08 2010-12-16 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
US8293881B2 (en) 2009-06-12 2012-10-23 Acceleron Pharma Inc. Isolated nucleic acid encoding a truncated ActRIIB fusion protein
CA2781152A1 (en) 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
CA2817008A1 (en) 2010-11-08 2012-05-18 Acceleron Pharma Inc. Actriia binding agents and uses thereof
CN103492416A (en) 2011-04-15 2014-01-01 默克专利股份公司 Anti- IL-1R1 inhibitors for use in cancer
MX366336B (en) 2012-11-02 2019-07-05 Celgene Corp Activin-actrii antagonists and uses for treating bone and other disorders.
CA2951926A1 (en) 2014-06-13 2015-12-17 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
SI3170005T1 (en) 2014-07-18 2019-08-30 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
US10519218B2 (en) 2014-12-01 2019-12-31 Ferring B.V. Selective IL-6-trans-signalling inhibitor compositions

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
WO1991018982A1 (en) * 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
EP1586635A1 (en) * 1990-06-28 2005-10-19 Hoechst Aktiengesellschaft Fusion proteins with parts of immunoglobulins, their production and use
EP0533006A1 (en) * 1991-09-18 1993-03-24 F.HOFFMANN-LA ROCHE & CO. AKTIENGESELLSCHAFT Chimaeric interleukin 5-receptor/immunoglobulin polypeptides
JP3122139B2 (en) * 1991-10-15 2001-01-09 マラーキー,ミッシェル,エフ. Therapeutic compositions of the late phase inflammatory response
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
JP3598386B2 (en) * 1992-03-09 2004-12-08 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ A nucleic acid sequence indicating the genetic code of an interleukin-9 receptor, or a nucleic acid sequence complementary to said nucleic acid sequence
US8211422B2 (en) * 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
WO1993019163A1 (en) * 1992-03-18 1993-09-30 Yeda Research And Development Co, Ltd. Chimeric receptor genes and cells transformed therewith
AT242322T (en) * 1992-03-30 2003-06-15 Immunex Corp Fusion protein that contains two receptors of the tumornescrose factor
JP3255699B2 (en) 1992-04-23 2002-02-12 味の素株式会社 Human IL-2 receptor γ chain molecule
CA2160011A1 (en) * 1993-04-06 1994-10-13 Philip D. Greenberg Chimeric cytokine receptors in lymphocytes
WO1995006737A1 (en) * 1993-09-03 1995-03-09 Kenneth Francis Prendergast Glycophorin binding protein (gbp130) fusion compositions
JPH09503673A (en) * 1993-10-14 1997-04-15 プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ Induction and maintenance methods of neuronal cells
US5470952A (en) 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
IL114825D0 (en) * 1994-08-04 1995-12-08 Regeneron Pharma Rtk/cytokine receptor chimeras
AU3830895A (en) 1994-10-07 1996-05-02 Amgen Boulder Inc. Dimeric il-4 inhibitors
US5837544A (en) * 1995-02-02 1998-11-17 Cell Genesys, Inc. Method of inducing a cell to proliferate using a chimeric receptor comprising janus kinase
US5837816A (en) * 1995-05-10 1998-11-17 Chiron Corporation Interleukin-2 receptor subunit ectodomain fusion protein comprising a leucine zipper domain
GB9526131D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US5776731A (en) * 1996-02-21 1998-07-07 Immunex Corporation DNA encoding type-I interleukin-I receptor-like protein designated 2F1
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
WO1998002558A2 (en) * 1996-07-17 1998-01-22 University Of Medicine And Dentistry Of New Jersey Chimeric receptors for jak-stat signal transduction
AU7011696A (en) * 1996-08-26 1998-03-19 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
GB9625899D0 (en) 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
US6087116A (en) * 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
AT272114T (en) * 1998-01-23 2004-08-15 Immunex Corp Receptors for il-18

Also Published As

Publication number Publication date
DE69922269D1 (en) 2004-12-30
ES2233733T3 (en) 2005-06-16
PL348529A1 (en) 2002-06-03
WO2000018932A9 (en) 2000-08-31
JP3902728B2 (en) 2007-04-11
NO20011513D0 (en) 2001-03-23
EP1115876A2 (en) 2001-07-18
US6472179B2 (en) 2002-10-29
CN100345970C (en) 2007-10-31
EP1229047A3 (en) 2002-10-02
US20020012962A1 (en) 2002-01-31
EP1229047B1 (en) 2004-11-24
BE2010C021I2 (en) 2018-12-04
PL201246B1 (en) 2009-03-31
DE69922269T2 (en) 2005-12-01
NO2011003I2 (en) 2011-04-11
IL142103D0 (en) 2002-03-10
AU758970C (en) 2007-05-03
WO2000018932A2 (en) 2000-04-06
AU6499499A (en) 2000-04-17
DK1229047T3 (en) 2005-02-21
CA2345109A1 (en) 2000-04-06
DE69932832T2 (en) 2007-02-08
AU758970B2 (en) 2003-04-03
HK1035377A1 (en) 2006-10-20
ES2267300T3 (en) 2007-03-01
IL142103A (en) 2007-07-04
NO20011513L (en) 2001-05-25
DE122010000023I2 (en) 2012-04-26
DE69932832D1 (en) 2006-09-28
DE122010000023I1 (en) 2012-04-26
CN1357049A (en) 2002-07-03
PT1229047E (en) 2005-03-31
EP1115876B1 (en) 2006-08-16
CA2345109C (en) 2012-12-18
WO2000018932A3 (en) 2000-11-02
EP1229047A2 (en) 2002-08-07
NO329976B1 (en) 2011-01-31
AT283365T (en) 2004-12-15
JP2002525119A (en) 2002-08-13
US20020164690A1 (en) 2002-11-07
NZ510720A (en) 2003-11-28
NO2011003I1 (en) 2011-05-02
EP1405915A1 (en) 2004-04-07

Similar Documents

Publication Publication Date Title
DE60031949D1 (en) Pcb and method for the production thereof
DE69735108D1 (en) A-1-adenosine receptor antagonist
DE59913881D1 (en) Nano capsules and method for the production thereof
DK1141274T3 (en) Soluble receptor BR43x2 and method for its use
DE69834699D1 (en) New protein and method for the production thereof
DE59813983D1 (en) Substituted 2-aryl-4-amino-chinazolines, method for the production thereof and their use as medicaments
DE69934890D1 (en) Glycosulfopeptides and process for their production and their use
DK1009732T3 (en) 1-Amino-alkylcyclohexane NMDA receptor antagonists
DE60027564D1 (en) Tek antagonists
DE69936050D1 (en) Graben-gate semiconductor components and method for the production thereof
DE60008912D1 (en) Directly compressible, ultrafine acetaminophene compositions and method for the production thereof
DE60031772D1 (en) Biochip and method for the production thereof
DE60023023D1 (en) Zirconium dioxideol and method for the production thereof
DE69732431D1 (en) Bone cement and method for the production thereof
DK0944619T3 (en) Hitherto unknown integrin receptor antagonists
DE59913933D1 (en) Ion-leading, substituted composite, method for the production thereof, and the use of the composite material
DE69910054D1 (en) Floor coating material and method for the production thereof
DE50006694D1 (en) High-temperature-resistant component and method for producing the high-temperature-resistant component
DE60132554D1 (en) Statorblechkörper and method for the production thereof
DE69922269D1 (en) IL-1 receptor fusion proteins used as antagonists and methods for their use and manufacture
DE69920459D1 (en) Heat management device and method for the production thereof
DE60036294D1 (en) Covered transponder and method for the production thereof
DE60005393D1 (en) Heat-absorbing filter and method for the production thereof
DE69819572D1 (en) Tubular container and method and device for the production thereof
DE69930254D1 (en) Microstructive engineering and method for the production thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1115876

Country of ref document: EP